The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and Daiichi Sankyo's Datroway became the first to cross the FDA's finish line.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC
Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
New First-Line Option Approved in Triple-Negative Breast Cancer
EU and US advisers split over AstraZeneca breast cancer drug
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an…
The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi…
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with…
AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic…
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of…
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
